A study to evaluate the effects of PF-03526299 on asthmatic subjects

• Research type

  Research Study

• Full title

  A randomized, double-blind, double-dummy, placebo-controlled, 3-way crossover study to determine the effects of inhaled doses of PF-03526299 on allergen-induced airway responses in mild asthmatic subjects

• IRAS ID

  21339

• Contact name

  Darren Wilbraham

• Eudract number

  2009-011421-14

• ISRCTN Number

  No number provided

• Clinicaltrials.gov Identifier

  No number provided

• Research summary

  PF-03526299 is an investigational drug being evaluated for the treatment of allergic asthma. The purpose of this study is to find out the effect of PF-03526299 on the lung function of patients with allergic asthma in comparison witfluicasone (a licensed steroid inhaler for asthma) and placebo (dummy drug) in healthy young mild asthmatic volunteers. This study will involve approximately 12 volunteers at up to 3 centres.The study involves 3 screening visits and 3 study periods with a gap of 21 days in between each period. At each study period, the volunteer will attend the Research Unit on Day 0 (admission) andbe dosed on the following day (Day 1).They will be discharged from the Research Unit on the evening of Day 1. There will also be a follow up visit 7 to 14 days after the final dosing.This study will be conducted at clinical pharmacology units within the UK.

• REC name

  London - London Bridge Research Ethics Committee

• REC reference

  09/H0804/50

• Date of REC Opinion

  20 May 2009

• REC opinion

  Further Information Favourable Opinion